Cargando…

Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial

STUDY OBJECTIVE: The objective of this was to evaluate the effectiveness of misoprostol in premenopausal nulliparous women with 200-mcg single vaginal dose 4 h before the procedure. DESIGN: This was a prospective randomized double-blind placebo-controlled trial. SETTING: This study was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Vinod G., Roy, Kallol Kumar, Rai, Rakhi, Das, Anamika, Bharti, Juhi, Zangmo, Rinchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394087/
https://www.ncbi.nlm.nih.gov/pubmed/32792757
http://dx.doi.org/10.4103/jhrs.JHRS_149_19
_version_ 1783565166468661248
author Nair, Vinod G.
Roy, Kallol Kumar
Rai, Rakhi
Das, Anamika
Bharti, Juhi
Zangmo, Rinchen
author_facet Nair, Vinod G.
Roy, Kallol Kumar
Rai, Rakhi
Das, Anamika
Bharti, Juhi
Zangmo, Rinchen
author_sort Nair, Vinod G.
collection PubMed
description STUDY OBJECTIVE: The objective of this was to evaluate the effectiveness of misoprostol in premenopausal nulliparous women with 200-mcg single vaginal dose 4 h before the procedure. DESIGN: This was a prospective randomized double-blind placebo-controlled trial. SETTING: This study was conducted in a tertiary care and academic research center. PATIENTS: One hundred patients were included in the study: 50 in misoprostol group and 50 in placebo. INTERVENTIONS: Patients underwent office hysteroscopy 4 h after vaginal application of misoprostol or placebo. MEASUREMENTS AND MAIN RESULTS: Ease of doing hysteroscopy was significantly better in the misoprostol group (difficulty score: 2.74 ± 1.20) as compared to placebo (difficulty score: 4.20 ± 1.10), P = 0.001. The time taken for negotiating the internal os (cervical passage time) was found to be significantly shorter in the misoprostol group (6.20 ± 5.21 s) as compared to placebo (14.78 ± 11.84 s), P = 0.001. The overall Visual Analog Scale (VAS) score was significantly lower in the intervention group (2.64 ± 1.62) as compared to placebo (4.90 ± 1.90), P = 0.001. Moreover, the VAS score at the point of passing internal os was significantly lower in the misoprostol group (2.82 ± 1.39) as compared to placebo (4.94 ± 1.96), P = 0.001. Misoprostol had a significant positive effect on satisfaction level of patients; 76% (n = 38) of women in the misoprostol group expressed their willingness to undergo the procedure again if required versus 18% (n = 9) in placebo, P = 0.001. Furthermore, 78% (n = 39) of women in the misoprostol group would recommend the procedure to their friends and relatives versus 36% (n = 18) in placebo, P = 0.001. CONCLUSION: Preoperative cervical preparation with 200 mcg of misoprostol vaginal application 4 h before office hysteroscopy in premenopausal nulliparous women significantly reduces the difficulty encountered in negotiating the cervical canal. Further, it significantly reduces the pain experienced by the patient at the point of passage through internal os as well as throughout the entire procedure.
format Online
Article
Text
id pubmed-7394087
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-73940872020-08-12 Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial Nair, Vinod G. Roy, Kallol Kumar Rai, Rakhi Das, Anamika Bharti, Juhi Zangmo, Rinchen J Hum Reprod Sci Original Article STUDY OBJECTIVE: The objective of this was to evaluate the effectiveness of misoprostol in premenopausal nulliparous women with 200-mcg single vaginal dose 4 h before the procedure. DESIGN: This was a prospective randomized double-blind placebo-controlled trial. SETTING: This study was conducted in a tertiary care and academic research center. PATIENTS: One hundred patients were included in the study: 50 in misoprostol group and 50 in placebo. INTERVENTIONS: Patients underwent office hysteroscopy 4 h after vaginal application of misoprostol or placebo. MEASUREMENTS AND MAIN RESULTS: Ease of doing hysteroscopy was significantly better in the misoprostol group (difficulty score: 2.74 ± 1.20) as compared to placebo (difficulty score: 4.20 ± 1.10), P = 0.001. The time taken for negotiating the internal os (cervical passage time) was found to be significantly shorter in the misoprostol group (6.20 ± 5.21 s) as compared to placebo (14.78 ± 11.84 s), P = 0.001. The overall Visual Analog Scale (VAS) score was significantly lower in the intervention group (2.64 ± 1.62) as compared to placebo (4.90 ± 1.90), P = 0.001. Moreover, the VAS score at the point of passing internal os was significantly lower in the misoprostol group (2.82 ± 1.39) as compared to placebo (4.94 ± 1.96), P = 0.001. Misoprostol had a significant positive effect on satisfaction level of patients; 76% (n = 38) of women in the misoprostol group expressed their willingness to undergo the procedure again if required versus 18% (n = 9) in placebo, P = 0.001. Furthermore, 78% (n = 39) of women in the misoprostol group would recommend the procedure to their friends and relatives versus 36% (n = 18) in placebo, P = 0.001. CONCLUSION: Preoperative cervical preparation with 200 mcg of misoprostol vaginal application 4 h before office hysteroscopy in premenopausal nulliparous women significantly reduces the difficulty encountered in negotiating the cervical canal. Further, it significantly reduces the pain experienced by the patient at the point of passage through internal os as well as throughout the entire procedure. Wolters Kluwer - Medknow 2020 2020-07-09 /pmc/articles/PMC7394087/ /pubmed/32792757 http://dx.doi.org/10.4103/jhrs.JHRS_149_19 Text en Copyright: © 2020 Journal of Human Reproductive Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Nair, Vinod G.
Roy, Kallol Kumar
Rai, Rakhi
Das, Anamika
Bharti, Juhi
Zangmo, Rinchen
Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title_full Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title_fullStr Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title_full_unstemmed Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title_short Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial
title_sort effectiveness of misoprostol in office hysteroscopy in premenopausal nulliparous women: a prospective randomized double-blind placebo-controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394087/
https://www.ncbi.nlm.nih.gov/pubmed/32792757
http://dx.doi.org/10.4103/jhrs.JHRS_149_19
work_keys_str_mv AT nairvinodg effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT roykallolkumar effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT rairakhi effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT dasanamika effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT bhartijuhi effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT zangmorinchen effectivenessofmisoprostolinofficehysteroscopyinpremenopausalnulliparouswomenaprospectiverandomizeddoubleblindplacebocontrolledtrial